ECCO 2024

The quest for predictive markers goes on...

S1P-Modulators from a safety perspective

Real-world data from a H2H-study on Vedolizumab vs.…

Primary sclerosing cholangitis – lessons from a large…

Combination of different drug classes - risks and…

Finally here: controlled trials in surgery!

A spotlight on the PROFILE study

Treatment targets in 2024 - a silent revolution

IL-23 in UC

Ustekinumab first, anti-p19 second?

Next chapter in S1P- and JAK-inhibition

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

Darvadstrocel for complex perianal fistulas and Crohn’s…

Mirikizumab vs Ustekinumab

VIVID 1: Mirikizumab in Crohn's Disease

PIZZICATO - new JAKies for crohn's disease

Tregs - a treatment for the future?

Results of the phase II PIZZICATO (ritlecitinib &…

Mirikizumab in moderate to severe Crohn’s disease:…

Changing the PROFILE of how we treat CD

Mirikizumab in crohn's disease

Mirikizumab vs Ustekinumab

Mirikizumab bei Morbus Crohn

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC:…

PIZZICATO - neue JAKs für Morbus Crohn

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na…

The efficacy of biologics and small molecules in…

Risankizumab & guselkumab in ulcerative colitis

Long term outcome of Obefazimod in UC

Mirikizumab in anti-TNF failures with UC

VTX002 (S1P-modulator) & obefazimod in ulcerative…

VTX002 (S1P-Modulator) & Obefazimod bei Colitis…

VTX-002 in pazienti con colite ulcerosa da moderata a…

lange-termijns uitkomst van obefazimod in UC

Risankizumab & Guselkumab bei Colitis Ulcerosa

Therapy in transition

Still a long road ahead in standards of care in IBD –…

Therapie im Umbruch

Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na…

PROFILE: Biomarkers not successfull for therapy…

Should we proactively treat CD-patients having small…

PROFILE: practice-changing results

Biomarker for biological loss of response in CD?

Changing treatment paradigm in CD

Early intervention in Crohn´s disease therapy

Results from the PROFILE-trial

Risultati dallo studio PROFILE

Faut-il traiter les patients avec les lesions de Crohn…

PROFILE: Biomarker nicht erfolgreich zur Prädiktion der…

Injection de cellules souches mesenchimateuses…

Biomarker for biological loss of response in CD?

Intervenção terapêutica precoce na doença de Crohn

Towards the proactive management of AS-UC responding to…

Vers un traitement plus agressif de la colite aigüe…

Personalized treatment in IBD: reality or hype?

Therapy in transition

HD-WLE with segmental reinspection is not inferior to…

Immunohomeostasis by regulatory CAR-T cells!?

Immunohomöstase durch regulatorische CAR-T-Zellen!?

Utilizzo di cellule CAR Tregs nelle MICI: dati…

Therapie im Umbruch

HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της…

Extended mesenterectomy is not superior to mesenteric…

No changes to surgical techniques for ileosecal…

Colectomy and the natural history of PSC – lessons form…

Randomised clinical trials finally coming to IBD…

MIRACLE project: Avoidance of protective Ileostomy

End of the Kono-S legend!

Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της…

Kolektomia a historia naturalna PSC – czy istnieje…

Implicazioni della proctocolectomia in pazienti affetti…

La fin de la legende du Kono-S!

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

Transcriptomic profiles in patients with UC receiving…

Molekulare Effekte der IL-23p19-Blockade